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Detection of donor-specific hyporesponsiveness following late
failure of human renal allografts
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Detection of donor-specific hyporesponsiveness following late failure of
human renal allografts. Limiting dilution assays to measure the frequency
of interleukin-2-secreting peripheral blood T cells were carried out in
patients, whose renal allografts had failed due to acute rejection (9
patients) and in patients whose grafts failed more than two years after
transplantation without any recent evidence of acute rejection. Using a
modified form of the assay we demonstrate that nearly half of 18 patients
whose renal transplants had failed after more than two years have low or
undetectable HTLp frequencies against donor, but not third-party DR
antigens. No such difference was observed in any of the nine patients
studied whose transplants were lost from early acute rejection. These
results provide the first indication that, as in rodent models of transplan-
tation, T cell unresponsiveness towards donor MHC antigens can occur
following prolonged residence of an allograft in humans. Furthermore, the
results suggest that chronic rejection may be driven by mechanisms other
than direct allorecognition. The assay may be a valuable tool to study the
evolution of donor-specific direct T cell alloresponsiveness in patients with
well-functioning grafts.
Over the past twenty years, with the advent of improved
immunosuppressive protocols, there has been a marked improve-
ment in the one-year graft survival of cadaver renal transplants.
Unfortunately, there has been virtually no change in the subse-
quent rate of graft loss over the same period, and the half-life of
cadaveric renal transplants surviving 12 months averages seven to
eight years. After the first year graft loss is most often attributed
to chronic rejection, the underlying mechanisms of which are
unclear, but may be immunologically mediated. In rodent models
of transplantation acute rejection resulting in graft loss may be
prevented by a short course of a variety of immunosuppressive
agents, following which long-term graft acceptance generally
occurs and chronic rejection is not a prominent feature. Further-
more, in experimental models prolonged graft residence may be
associated with donor-specific helper T cell unresponsiveness or
tolerance. This has not been demonstrated before in humans.
It is well established that CD4 T cells are central to acute graft
rejection [1], and data from experimental animal models of
transplantation suggest that the subset of T cells secreting inter-
leukin-2 (IL-2) are particularly important. This is consistent with
evidence that T cell-mediated cytotoxicity and/or delayed type
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hypersensitivity are the major effector mechanisms of graft rejec-
tion. The precursor frequencies of alloreactive IL-2-secreting
CD4 T cells might therefore be related to the strength of the
alloresponse following transplantation. Limiting dilution analysis
provides a method of precisely quantitating the alloreactive T cell
repertoire. A sensitive limiting dilution assay to measure precur-
sor frequencies of IL-2-producing T cells, in which an indicator
cell line is added directly to the microcultures, has been described
[2, 3]. A modification of the assay, based on differential sensitivity
of IL-2 production to y-irradiation, distinguishes unstimulated or
naive from primed or conditioned T helper cells. T cells that have
previously seen antigen and been stimulated are subsequently
capable of IL-2 production even after y-irradiation and have been
described as primed or conditioned. These assays have been used
previously to study a murine model of transplantation using either
subcutaneously implanted synthetic sponges injected with alloge-
neic spleen cells or skin grafts [31. Conditioned helper T cell
precursor frequencies were high in blood, while conditioned
cytotoxic T cell precursor frequencies were undetectable, al-
though they were high within the grafts and the draining lymph
nodes. Furthermore, conditioned helper T cell precursor frequen-
cies remained detectable for at least 60 days following rejection of
skin grafts [41. The relative resistance of primed as compared to
naive T cells to cyclosporine is a further reason why primed
frequencies might be expected to be of greater predictive signif-
icance than total or naive T cell frequencies in clinical transplan-
tation.
Preliminary work from this laboratory showed that in two renal
transplant recipients whose allograft failed more than two years
after transplantation, the primed helper T lymphocyte precursor
(HTLp) frequencies in the peripheral blood were low against
HLA-DR alloantigens expressed by the failed grafts, compared to
frequencies measured against other HLA-DR alloantigens [5, 6].
We now report that nearly half of 18 patients whose renal
transplants had failed after more than two years have low or
undetectable HTLp frequencies against donor, but not third-party
DR antigens. In contrast, in the nine patients studied whose
transplants were lost from early acute rejection, HTLp frequeri-
cies against donor and third-party DR antigens were of the same
order of magnitude. These data suggest that helper T cell
precursor frequency measurements will be valuable in predicting
the strength of the in vivo alloresponse following transplantation.
This prediction is supported by our recent findings in bone
marrow transplant recipients in which anti-recipient alloreactive T
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Table 1. Patient details
Patient Donor Fail-test
DR DR Time txp Txp time
Patient type type functioned' in situ" ISC yearsd
1 1, 13 6, 7 59 days no steroids 14
2 7, 8 1, 15 166 days no triple 3
3 13, 13 3 7 days no triple 2
4 1, 2 1, 4 8 days no triple 10
5 1, 13 (i) 2 120 days no pred/aza 6
(ii) 4, 7 127 days yes triple 5
6 7, x (i) 2, 7 39 days no steroids 8
(ii) 3, 11 0 days no triple 7
7 5, 6 3, 7 30 days no pred/aza 9
8 2, 9 2, 7 24 days no triple 6
9 1, x 4, 13 356 days no CsA only 8
10 2, 6 2, 5 3.5 years no pred/aza 5
11 5, 6 2, 4 2.25 years yes triple 5
12 5, 6 or 8 1, 4 4.0 years no triple 4
13 7, x 4, 12 5.5 years yes triple
14 3, 5 1, 7 2.1 yes triple 3
15 6, x 4, x 6.8 years yes triple 1
16 3, 6 6, 7 9.5 years yes pred/aza I
17 3, 15 4, 7 2.1 years no triple 1
18 7, 13 2, 4 4.9 years yes triple 2
19 10, 11 3, 11 2 years yes triple 4
20 8, 10 4, 7 3.0 years no triple
21 3, 7 4, 5 3.25 years yes triple 2
22 13, x 2, 6 5.6 years yes CsA only 3
23 4, x 15, 4 6.6 years yes triple 3
24 2, ?6 ? 5.6 years yes pred/aza 3
25 3, x 3, 4 2.1 years yes triple 1
26 5, 6 9, x 6.9 years yes triple
27 2, x 3, x 2.9 years no triple 4
Time the renal transplant functioned
h Whether or not the failed graft was still O Situ at the time of study
Immunosuppressive treatment given during the period the transplant
functioned (triple-prednisolone, azathioprine and cyclosporine)d Time between graft failure and study
cell precursor frequencies in donor blood correlated with the
incidence of graft-versus-host disease [7].
Methods
Patients
Twenty-seven renal transplant recipients whose grafts had
failed were studied. The chronic loss group consisted of 18
patients whose kidney grafts failed due to chronic rejection more
than two years after transplantation. In the acute loss group of 9
patients, transplants had failed within the first year of transplan-
tation (7 within 2 months), following aggressive acute rejection.
All patients had been back on dialysis and off all immunosuppres-
sive drugs for at least one year. In all cases the previous
transplants had expressed at least one mismatched HLA-DR
antigen. Patient details are shown in Table 1.
CTLL-2 cells
This murine cell line responds to murine IL-2 and interleukin-4
(IL-4) but only to human IL-2. The cells are maintained in culture
in RPMI-1640 supplemented with glutamine (2 mmol/liter), pen-
icillin/streptomycin (50 U/mI), 5% fetal calf serum, 1 mmol/liter
pyruvate and 5 x 10 M 2-mercaptoethanol (all from Flow
Laboratories) and human recombinant IL-2 (rIL-2, 10 U/mI;
Boehringer Mannhcim, Germany). They were sub-cultured every
Workshop no. DR type
9001 DR1
9017 DRw15
9019 DR3 DRw17
9029 DR4 Dw4
9030 DR4 Dw13
9038 DR5(12) B6
9043 DRw1I Dw5
9065 DRw13 Dw18
9053 DRw13 Dw19
9050 DR7 Dw17
9067 DR8 Dw8.1
The numbers are those assigned by the Xth Histocompatibility Work-
shop [8].
two to three days. Prior to use they were washed three times and
cultured in medium without IL-2 for 18 hours.
Responder cells
Peripheral blood mononuclear cells (PBMC) were separated
from patients' blood by density gradient centrifugation over
Lymphoprep (Nygaard). PBMC were depleted of CD8 cells by
incubation with anti-CD8 monoclonal antibody (OKT8, ATCC)
followed by magnetic beads (Dynal) separation. Efficacy of deple-
tion was measured by flow cytometry and the final population was
always 2% CD8. The depleted cells were stored in liquid
nitrogen until assayed.
Stimulator cells
A range of B-lymphoblastoid cell lines (B-LCL) of defined
homozygous DR type from the Xth International Histocompati-
bility Workshop [8] were used as stimulator cells (Table 2). They
were maintained in culture in supplemented RPMI-1640 tissue
culture medium with 5% fetal calf serum.
T cell clones
To establish the sensitivity of the assay, a number of human
CD4 anti-DR1 T cell clones [9] as responder cells were assayed
in limiting dilution against DR1- and control DRwI7-expressing
B-LCL under identical conditions to those used for patient CD4
T cells.
Limiting dilution assay
The assay is sensitive and is based on a bioassay for IL-2
production using the CTLL indicator cell line. The assay has been
modified from that previously described [2, 3].
Total limiting dilution assay. The assay was performed in sup-
plemented RPMI with 5% human AB serum. Each responder was
tested against B-LCL expressing donor DR antigens and against
at least four other lines expressing third party DR alloantigens.
The number of third-party cell lines tested depended upon the
number of responder cells available. Replicates of 24 wells at 7
doubling dilutions of responder cells (from ito 2 X iO per well)
in 50 pA of medium were aliquoted into wells, and medium alone
was added to 24 control wells. Irradiated (200 Gy) B-LCL cells
(2 >< io in 50 pJ) were added to all wells. After 20 hours the
plates were irradiated (20 Gy), followed by the addition of 2 X iO
CTLL cells in 50 pA to each well. After a further eight hours the
Table 2. DR types of the EBV lines used as stimulator cells
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Table 3. Measured precursor frequencies of anti-DR1 clones
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Clone
Total
1/frequency
95% Confidence
interval x2 P value
Primed
1/frequency
95% Confidence
interval P value
03 1.5 1.1—2.0 4.6 > 0.1 3.3 2.5—4.4 4.6 > 0.1
G3 1.8 1.4—2.4 2.9 >0.1 4.2 3.1—7.1 5.2 >0.1
G8 2.4 1.8—3.1 1.4 > 0.1 37 2.9—5.0 9.5 > 0.1
Gil 4.2 3.2—7.1 5.6 >0.1 71.5 45.2—113.1 14.6 = 0.05
G12 2.4 1.9—3.2 5.9 > 0.1 8.4 6.4—10.9 13.2 > 0.05
PG4 4.3 3.2—5.8 10.8 > 0.1 v low
PG12 2.1 1.6—2.8 3.6 > 0.1 3.0 2.3—3.9 L5 > 0.1
A range of anti-DR1 specific human T cell clones were used as responder cells in limiting dilution assays to measure total and primed frequencies
(see Methods). The frequencies against no stimulator cells and DRwi7 expressing cells were undetectable.
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wells were pulsed with 0.2 iCi of 3H-thymidine (25 mCi/mmol;
Amersham International plc, Amersham, UK) in 25 jd, and the
plates were harvested 16 hours later and counted by liquid
scintillation spectrometry (LKB, Turu, Finland). In all experi-
ments a dose-dependent proliferation of CTLL-2 cells was con-
firmed by incubation with a range of rlL-2 concentrations.
Primed limiting dilution assay. Responder cells were irradiated
(20 Gy) prior to culture with B-LCL stimulator cells prepared as
for the total assay. Replicates of 24 wells of 7 doubling dilutions of
responder cells (from 2 to 4 1< io per well) were aliquoted into
wells in 50 p1 of medium together with 2 X i04 irradiated (200 Gy)
B-LCL. CTLL cells (2 X 10) were added one hour later, and the
remainder of the assay was then identical to the total assay.
Calculation of precursor frequencies. Wells were scored positive
if the counts were greater than the mean plus 3 SDS of control wells
(with stimulator, CTLL but no responder cells). The frequency,
confidence interval and x2 value for each assay were calculated by
the maximum likelihood method [101 using GLIM software (NAG
Ltd., Oxford, UK). For all data sets presented for which a
measurable frequency was obtained, the P value was > 0.05,
confirming that the experiments conformed to single-hit kinetics.
Assays for which the P value was < 0.05 were discarded.
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Fig. 1. Scatter plot of total HTLp frequencies
against different DR alloantigens measured in
CD4 T cells from patients with failed renal
transplants. Transplants failed within one year
in patients 1 to 9, and after two years in
patients 10 to 27. Symbols are: (•) HTLp
frequencies against stimulator cell lines
expressing donor DR-antigens; (0) HTLp
frequencies against stimulator cell lines
expressing third-party DR-antigens.
0 0 Fig. 2. Scatter plot of primed HTLp frequencies0 against different DR alloantigens measured in
0 CD4 T cells from patients with failed renal
• transplants. Transplants failed within one year
in patients 1 to 9, and after two years in
patients 10 to 27. Symbols are: (•) HTLp
o frequencies against stimulator cell lines
expressing donor DR-antigens; (0) HTLp
frequencies against stimulator cell lines
8 9101112131415161718192021222324252627 expressing third-party DR-antigens. Theinterrupted line indicates the level of sensitivity
Patients of the assay.
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Reproducibility of the assays. During development of the assay
reproducibility was established using blood from healthy volun-
teers and patients on dialysis. Assays were performed on different
occasions using lymphocytes prepared on the same day as well as
on different days over a six months period. In general the repeat
frequencies were similar with overlapping 95% confidence inter-
vals, and with similar relative frequencies when several stimulator
cells were used.
Results
The IITLp assay is capable of detecting IL-2 secretion from a
single cell
To assess the sensitivity of the assay, limiting dilution cultures
were performed using anti-DR1 alloreactive T cell clones as
responder cells and a DR1-positive B cell line as stimulator cell.
The results of assays using five different clones are shown in Table
3. Since it is unlikely that every single T cell in a clonal population
will be in a position to respond to antigen, we conclude that the
total assay is capable of detecting a single IL-2-secreting T cell. All
T cell clones would be expected to be primed, although the
primed assay consistently measured a lower frequency than the
total assay (Table 3). Presumably -y-irradiation impairs the ability
of the T cells to secrete IL-2, although the various clones exhibited
differences in radiation susceptibility. For three clones (G3, G8
and PG12), the measured primed frequency was only slightly
lower than the total frequency (1 to 2 times lower), while for
others (Gil and PG4) the primed frequency was much lower. It is
likely that optimal stimulation of these latter clones produce less
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Fig. 3. Limiting dilution plots of primed HTLp
frequency assays for 2 patients. (A) patient 1
whose transplant failed early (56 days) and (B)
patient 13 whose transplant failed late (5.6
years). The lines represent those calculated to
fit the data best (Methods) and from which the
frequency was derived. Symbols are: (U)
stimulator cell lines expressing donor
DR-antigens; () stimulator cell lines
expressing third-party DR-antigens.
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IL-2 per cell since the measured total frequencies were approxi-
mately 1 in 4 rather than being nearer to 1 in 1, as was the case for
the other clones tested.
No differences in total HTLp frequencies were detected between
the two patient groups
Seventy total HTLp assays were performed in 14 patients. Five
assays were excluded either because P < 0.05 or for other
technical reasons. There were no differences between the total
HTLp frequencies measured against B-LCL cells expressing
donor and third-party DR antigens in any of the first fifteen
patients studied (Fig. 1). Consequently, only the primed HTLp
frequencies were measured in the remaining 13 patients.
The primed HTLp frequencies against donor DR alloantigens were
undetectable in 7 out of 17 chronic loss patients
One hundred and fifty primed HTLp frequencies were mea-
sured in 27 patients with the rejection of 9 assays either because
P < 0.05 or for other technical reasons. These HTLp frequencies
were lower than the total HTLp frequencies in all patients. The
results are displayed in Figure 2.
For patients whose grafts failed early, there were no differences
between HTLp frequencies measured against the B-LCL cells
expressing donor and third-party DR alloantigens, except for
patient 5. Within the group whose transplants functioned for
more than two years, 10 patients similarly showed no difference in
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frequencies towards donor and third-party DR alloantigens. How-
ever, strikingly in eight patients, the frequencies against one or
more of the donor DR-antigens were an order of magnitude lower
than any of the frequencies against third-party DR-antigens, and
were very low or undetectable in seven patients. Figure 3 shows
representative limiting dilution plots from two patients (numbers
1 and 13 from Table 1 and Fig. 2) with different patterns of HTLp
frequencies against donor and third-party DR alloantigens.
There were no obvious differences between these two groups of
patients in terms of the immunosuppression they had received
(Table 1). None of the nine patients whose grafts failed early had
the transplant in situ at the time of study (patient 5 had the DR4,7
but not the DR2 graft in situ, and frequency data were only
available against DR2 stimulator cells). In the group of patients
whose grafts failed after two years, the majority retained the
transplant in situ although the proportion was similar in those with
(5 of 8) and without (8 of 10) donor hyporesponsiveness.
Discussion
Helper T cell responses towards donor HLA antigens in
patients who have returned to dialysis following failure of a renal
transplant due to acute or chronic rejection have not previously
been addressed. When a transplant fails due to acute rejection, it
is reasonable to assume that sensitization occurs, since experimen-
tal models of transplantation suggest that such rejection results
from direct recognition of allogeneic, especially class II, MHC
molecules. In contrast, when graft failure results from chronic
rejection, the mechanisms of which are obscure, there is little
basis for making any assumption regarding the expansion of
donor-specific T cells. The findings reported here suggest that in
a significant proportion of patients whose grafts failed due to
chronic rejection, rather than sensitization low or unresponsive-
ness occurred in T cells with a direct allospecificity for donor DR
alloantigens. This finding, as discussed below, is immunologically
important but suggests that direct allorecognition is not respon-
sible for chronic rejection. There have been a large number of
factors implicated as mechanisms underlying chronic rejection
[11]. Although immunological mechanisms have been implicated,
especially in experimental models (see below), many non-immu-
nological factors including damage sustained during reperfusion,
low numbers of functioning nephrons, hypertension, hyperlipidae-
mia and drug toxicity have also been implicated. Since this study
addressed the question of the T cell responsiveness towards donor
and other alloantigens after rejection of renal transplants, non-
immunological parameters were not analyzed.
In experimental models of transplantation, the prolonged res-
idence of a vascularised allograft induces donor-specific T cell
tolerance. Although the mechanisms of this tolerance are not fully
understood, it is likely that it is, in part, the result of the encounter
by recipient T cells of donor alloantigens on the surface of
parenchymal cells of the allograft. Such parenchymal cells lack
specialised accessory cell function, and do not provide the key
co-stimulatory signals required for full activation of IL-2-secreting
T cells. It has been extensively documented in vitro that ligand
recognition on the surface of antigen-presenting or allostimulator
cells that lack co-stimulatory potential can inactivate the IL-2-
secreting pathway in the responder cell [12, 131. In a rat system,
Braun et al have shown that y-interferon-induced, MHC class
Il-expressing, renal tubular epithelial cells induce a state of
proliferative non-responsiveness in alloreactive T cells in vitro
[14]. Furthermore, the injection into an animal carrying a renal
allograft of in vitro-primed alloreactive T cells specific for donor
MHC alloantigens failed to induce graft rejection. In contrast, if
the same T cells were injected into a sub-lethally irradiated animal
at the time of transplantation, graft rejection ensued [14]. This
presumably reflects the ability of bone marrow-derived donor
antigen-presenting cells, transplanted with the graft, to stimulate
the injected T cells in vivo. However, in animals bearing an
established graft, from which donor bone marrow-derived cells
had been lost, the renal parenchymal cells were unable to activate
the alloreactive cells [14, 15]. The observations made in the
chronic loss patients studied here may parallel these experimental
findings. The low or undetectable donor-specific HTLp frequen-
cies were not found in all of the chronic loss patients. This is
perhaps not surprising, particularly when one considers all the
relevant factors which might falsely obscure such a result (see
below). However, we believe the observation that donor-specific
low or unresponsiveness occurs at all is highly informative.
These experiments do not reveal the mechanisms responsible
for the low or undetectable donor-specific HTLp frequencies in
the chronic patients. However, the LDA data conformed to single
hit kinetics suggesting that the presence of a population of
suppressor cells is unlikely to be the explanation. It is more likely
that hyporesponsive patients, exhibiting tolerance in their reper-
toire of T cells with direct anti-donor specificity, have a reduced
number of donor DR alloantigen-specific T helper cells. This
could be due either to clonal deletion or to the induction of
anergy.
Since all the patients' transplants in this study eventually failed,
an important issue that arises from these data is the mechanism of
chronic rejection. Both immunological and non-immunological
factors have been implicated, and it is possible that more than one
mechanism is responsible [121. The results obtained in these
patients suggest that this process does not reflect the activity of T
cells with a direct specificity for donor HLA class II alloantigens.
This does not exclude the possibility that an immunological
mechanism may be involved. It has long been appreciated that two
pathways of MHC allorecognition exist [15, 161. The direct
pathway is responsible for the uniquely high precursor frequency
of alloreactive T cells, and involves interaction between the
alloreactive T cell's receptor and the intact MHC alloantigen on
the surface of an allogeneic cell. The indirect pathway, on the
other hand results from the display of processed antigens as
peptides bound to self MHC restriction elements on the surface of
cells expressing a self MHC restriction element. This has been
demonstrated to occur [17], indeed, in a rat model of transplan-
tation antibodies to recipient MHC class II antigens blocked
rejection of rat kidneys expressing allogeneic MHC [18], and it has
been argued that indirect pathway T cells may contribute to
chronic rejection [191. T cells with indirect anti-donor specificity
would not have been detected in the assays used here since the
stimulator cells expressed only donor, and not self, DR molecules..
Assays to measure the precursor frequencies of T cells with
indirect allospecificity are currently being developed.
The modification of the assay that distinguished anti-donor
from anti-third party HTLp frequencies, at least in a proportion of
the patients, involved y-irradiation of the responder cells. As
shown with the alloreactive T cell clones, irradiation reduces the
sensitivity of the assay, presumably due to impairment of IL-2
secretion by responder cells, although not all clones had the same
radiation sensitivity. These findings indicate that this form of the
assay is not detecting primed, rather than naive, cells but may
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detect alloreactive T cells with higher avidity or with the capacity
to secrete relatively large amounts of IL-2. Addition of cyclospo-
tin to the cultures may have a similar differential effect on T cells,
as demonstrated recently for cytotoxic T cells [201. Whatever the
difference between the information provided by the two forms of
the assay, it may well be that the alloreactive cells detected by the
primed assay have the most aggressive properties in vivo, such that
this assay has predictive power in the transplant context. This
possibility is currently being explored.
Two additional questions arise from these data. First, why was
T cell low or unresponsiveness towards donor DR antigens only
detected in a proportion of patients with late graft failure? This
may reflect the inaccuracy of donor HLA typing. Clearly it would
have been preferable to have used only patients and donors whose
DR antigens had been accurately typed using molecular biological
methods. However, because we wished to study patients at least
one year after the loss of grafts which had functioned for many we
often had to rely on the original serological typing of the donor.
Thus incorrect B-LCL may have been used in assessing donor-
specific alloreactivity. Furthermore, sharing of DO and/or DP
types and/or DRB3/DRB4 gene products by the recipient and the
stimulator B-LCL may have created the possibility that EBV-
specific helper T cells contributed to the measured frequencies.
These confounding factors would all result in the measurement of
falsely high frequencies, so that the observation of T cell low or
unresponsiveness towards donor DR antigens in nearly half of the
chronic loss patients is even more striking.
Second, why was hypo- or unresponsiveness detected so long
after removal of the allograft in some patients? Experimental data
exists to suggest that tolerance has a relatively short memory. In
rodents, donor-specific tolerance appears to depend on the per-
sistence of alloantigen [21] and persists for approximately 100
days after removal of an antigen [221. There is no data to indicate
the longevity of T cell tolerance in the absence of antigen in
humans. It is conceivable that donor alloantigen persisted after
transplant removal, in the form of long-lived bone marrow-
derived cells that have been reported to seed the periphery of
renal transplant recipients [231.
These results provide the first indication that T cell low or
unresponsiveness towards donor HLA-DR antigens occurs in
humans. They also suggest that a mechanism other than direct
allorecognition by recipient T cells may be responsible for driving
chronic rejection. The application of this assay may be a valuable
tool to study the evolution of donor-specific direct T cell allore-
sponsiveness in patients with well-functioning grafts, and these
studies are the focus of continuing studies.
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